How does the microbiome affect liver disease?
AASLD LiverLearning®, Herbert Tilg, 164850
Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma
AASLD LiverLearning®, Ali Canbay, 164851
The scope of hepatology practice outside the traditional academic medical center
AASLD LiverLearning®, Marcelo Kugelmas, 164852
Novel treatments in primary sclerosing cholangitis
AASLD LiverLearning®, Keith Lindor, 164853
Clinical Hepatology Debrief
AASLD LiverLearning®, Arun Sanyal, 154738
Elimination of Hepatitis B: Is It possible?
AASLD LiverLearning®, Anna Lok, 154737
Hepatitis Debrief
AASLD LiverLearning®, Robert Brown, 154735
Pangenotypic Regimens and the Next Generation of HCV Treatment
AASLD LiverLearning®, Nancy Reau, 154728
Resistance Testing: Interpretation and Incorporation into Treatment Algorithms
AASLD LiverLearning®, Jordan Feld, 154727
Management of Acute Variceal Bleed
AASLD LiverLearning®, Shiv Kumar Sarin, 154734
Treatment of Persons Who Inject Drugs (PWID): Treatment as Prevention
AASLD LiverLearning®, Jason Grebely, 154726
Non-cirrhotic Portal Hypertension: Eastern Perspective
AASLD LiverLearning®, Hitoshi Maruyama, 154733
In memoriam: Maribel Rodrigez Torres
AASLD LiverLearning®, Norbert Brau, 155710
HCV Symposium: Challenges in the DAA Era: Program Chair
AASLD LiverLearning®, Norah Terrault, 154723
Patients with Renal Failure: When and How to Treat?
AASLD LiverLearning®, David Roth, 154725
TIPS: Is Early Intervention Helpful?
AASLD LiverLearning®, Florence Wong, 154732
Non-cirrhotic Portal Hypertension: Western Perspective
AASLD LiverLearning®, Theo Heller, 154731
AASLD-APASL Symposium: Portal Hypertension: Program Chair
AASLD LiverLearning®, Rajender Reddy, 154729
New Treatments for NASH
AASLD LiverLearning®, Brent Tetri, 154722
Advances in Non-invasive Assessment and Genetics of NAFLD
AASLD LiverLearning®, Christopher Paul Day, 154721
Advances in the Management of Alcoholic Liver Disease
AASLD LiverLearning®, Philippe MATHURIN, 154720
Differential Access to Direct Acting Antivirals (DAAs) Across Federal, State, Commercial, and Manufacturer Patient Assistance Programs (MPAP)
AASLD LiverLearning®, Jane Giang, 144651
Perceptions of HCV treatment and correlates to initiation willingness in HCV+ methadone clients
AASLD LiverLearning®, Amy Jessop, 144652
Symptom Clusters Generated using Factorial Analysis of PROMIS tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis
AASLD LiverLearning®, Jasmohan S. Bajaj, 144653
Effectiveness and security of 3D/2D treatment in HCV/HIV coinfected cirrhotic patients
AASLD LiverLearning®, MIGUEL ANGEL VON WICHMANN, 144909
The Real-World Israeli experience of treating chronic hepatitis C (CHC), genotype 1 (GT1) patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin (3D±R): a large multi-center cohort
AASLD LiverLearning®, Eli Zuckerman, 144910
Comparative Efficacy of an Intensified Re-Vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected with HIV (CORE-HIV): A Randomized Controlled Trial. Interim Analysis.
AASLD LiverLearning®, Jose Ignacio Vargas, 144667
Early hepatitis B surface antigen seroclearance after commencement of antiviral treatment in patients with de novo HBV reactivation
AASLD LiverLearning®, Haelim Lee, 144668
The role of IL-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection
AASLD LiverLearning®, Lung Yi Mak, 144669
Infection with multi-drug resistant organisms is associated with increased mortality in patients listed for liver transplantation.
AASLD LiverLearning®, Rosalie Oey, 144925
Early Fluid Resuscitation in Cirrhotic Patients Diagnosed with Severe Sepsis is Associated with Decreased In-Hospital Mortality
AASLD LiverLearning®, James Crismale, 144926
Quantitative Hepatitis B Surface Antigen Does Not Reliably Identify Patients with Active Hepatitis D Virus Infection
AASLD LiverLearning®, Matthew Sadler, 144683
Combined use of AST to platelet ratio index and Fibrosis-4 score can risk stratify hepatocellular carcinoma risk in chronic hepatitis B patients with low level viremia
AASLD LiverLearning®, Ji Hyeon Lee, 144684
US Asian HBV Patients Have Liver Steatosis and Metabolic Syndrome at Lower BMI than non Asians
AASLD LiverLearning®, William Clarke, 144685
Improved short-term survival in patients with Acute-on-Chronic Liver Failure (ACLF) in extremis with a combination therapy approach
AASLD LiverLearning®, Gaurav Pande, 144941
Opioid use is associated with all-cause and sepsis-related death among patients with cirrhosis
AASLD LiverLearning®, Steven Scaglione, 144942
Hepatitis B surface antigen titer is a good indicator of durable viral response after off-treatment of entecavir for chronic hepatitis B
AASLD LiverLearning®, Han ah Lee, 144699
Dynamic changes of liver stiffness predict histological reverse of liver fibrosis in chronic hepatitis B patients treated with entecavir
AASLD LiverLearning®, Yuanyuan Kong, 144700
Prediction of hepatitis B virus-related liver cancer incidence and recurrence after anticancer therapy by hybrid evaluation of serum WFA(+)-M2BP and hepatitis B core-related antigen
AASLD LiverLearning®, Kazunori Kawaguchi, 144701
Assess outcome of Slow low-dose continuous albumin,Furosemide with or without Terlipressin SIFA(T) infusion in patients of cirrhosis with refractory ascites
AASLD LiverLearning®, Gaurav Pande, 144957
Fatty acid-binding proteins (FABPs) levels are increased in decompensated cirrhosis and associated with poor outcomes
AASLD LiverLearning®, Isabel Graupera, 144958
The SNPs of HLA-DP are associated with HBsAg levels in chronic HBV infection
AASLD LiverLearning®, Ochi Yuka, 144716
Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA
AASLD LiverLearning®, Jens Verheyen, 144717
TLR-9 rs187084-dependent reduction of inflammatory and sympathetic responses to bacterial translocation in patients with decompensated cirrhosis
AASLD LiverLearning®, Paula Piñero Romero, 144973
Serum microRNA-122 as well as WFA(+)-M2BP is a good predictor of liver fibrosis in chronic hepatitis B infection
AASLD LiverLearning®, Masato Nakamura, 144718
Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis.
AASLD LiverLearning®, Troels Busk, 144974
Validation of a Mortality Risk Score to assess the Long-Term Prognosis of Chronic Hepatitis B Patients
AASLD LiverLearning®, Willem Pieter Brouwer, 144732
Switching to Tenofovir versus Continuing Entecavir in Chronic Hepatitis B Patients with Partial Virologic Response during Entecavir Therapy: STEEP Study
AASLD LiverLearning®, Hyung Joon Yim, 144733
The pan caspase inhibitor Emricasan improves the hepatic microcirculatory dysfunction of CCl4-cirrhotic rats leading to portal hypertension amelioration and cirrhosis regression
AASLD LiverLearning®, Jordi Gracia-Sancho, 144989
Predictive role of serum HBsAg and HBcrAg levels in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon-based therapy
AASLD LiverLearning®, Pisit Tangkijvanich, 144734
Circulating microparticles carry apoptosis markers CK-18 and caspase-3/7 which are reduced by treatment with Emricasan in subjects with chronic liver diseases
AASLD LiverLearning®, Akiko Eguchi, 144990
Comparison Of Markers Of Bone Turnover Demonstrates Less Changes In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared with Tenofovir disoproxil fumarate (TDF)
AASLD LiverLearning®, Wan-Long Chuang, 144748
Correlation of early biochemical and virologic responses during oral antiviral therapy for chronic hepatitis B
AASLD LiverLearning®, Maurizia Rossana Brunetto, 144749
Genotype Specific Differences In Magnitude Of HBsAg Reduction During TDF or tenofovir alfenamide (TAF) Therapy In CHB Patients
AASLD LiverLearning®, Patrick Marcellin, 144750
A Retrospective Study on the Clearance Rate of Hepatitis B Surface Antigen with Antivirus Treatment in 1 to 7 years old Children with HBeAg-positive Chronic Hepatitis B
AASLD LiverLearning®, Zhu Shishu, 144764
A randomized trial evaluating the antiviral efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant chronic hepatitis B patients with undetectable hepatitis B virus DNA
AASLD LiverLearning®, Jang Byoung Kuk, 144765
A real-world experience in baseline predictors of virological response to Peginterferon Alfa-2a in patients with HBeAg-negative chronic hepatitis B
AASLD LiverLearning®, Yi-Cheng Chen, 144766
A randomized study comparing tenofovir dispoxil fumarate and entecavir hydrate in Japanese patients with treatment naïve chronic hepatitis B
AASLD LiverLearning®, Wataru Sugiura, 144781
Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemo-embolization
AASLD LiverLearning®, Sun Hong Yoo, 144782
Comparison of Renal safety of Tenofovir (TDF) and Entecavir (ETV) in Patients with Chronic Hepatitis B (CHB): A Systematic Review with Meta-Analysis
AASLD LiverLearning®, Hyo Young Lee, 144783
Understanding the unmet need in Autoimmune Hepatitis - The United Kingdom AIH Study (UK-AIH)
AASLD LiverLearning®, Lin Lee Wong, 144539
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF), a Novel Immune-Modulating Biologic, in Autoimmune Hepatitis
AASLD LiverLearning®, Christopher O'Brien, 144540
Prevalence and Predictors of Fragility Fracture in Corticosteroid-treated Patients with Autoimmune Hepatitis (AIH)
AASLD LiverLearning®, Laura Harrison, 144541
Liver stiffness and virologic outcomes after introducing tenofovir as part of antiretroviral therapy in lamivudine-experienced adults with HIV and hepatitis B virus (HBV) co-infection in Ghana: four-year follow up of the prospective HEPIK cohort
AASLD LiverLearning®, Alexander Stockdale, 144797
Analysis of the incidence of primary hepatocellular carcinoma in Japanese patients with hepatitis B virus infection stratified by primary liver cancer risk score at the start of Entecavir therapy
AASLD LiverLearning®, Yoshiyasu Karino, 144798
Treatment efficacy of switching to tenofovir strategy over continued entecavir therapy in chronic hepatitis B patients with partial virologic response to entecavir
AASLD LiverLearning®, Jun Seop Lee, 144799
UK-AIH - Highlighting the need for standardization of treatment in autoimmune hepatitis
AASLD LiverLearning®, Lin Lee Wong, 144555
RNA-seq analysis identifies early gene signature associated with antifibrotic efficacy of dual combination therapy directed against lysyl oxidase-like 2 (LOXL2) and apoptosis signal-regulating kinase 1 (ASK1) in BALBc.Mdr2-/- mice
AASLD LiverLearning®, Yury Popov, 144556
IL-4 and IL-13 regulate liver fibrosis through M2 macrophages, but not Th2 T cells or hepatocytes
AASLD LiverLearning®, Shih-yen Weng, 144557
Predictors of Sustained Virological Response (SVR) after Direct Acting Antiviral (DAA) treatment for Hepatitis C: meta-analysis of 55 studies in 11,419 patients
AASLD LiverLearning®, Bryony Simmons, 144813
Efficacy and safety of ombitasvir/ritonavir/paritaprevir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease
AASLD LiverLearning®, Taeang Arai, 144814
Treatment of chronic HCV Infection with direct antiviral agents (DAA) results in rapid regression of transient elastography (Fibroscan®) and validated fibrosis markers FIB-4 and APRI
AASLD LiverLearning®, Jacqueline Bachofner, 144815
Advanced glycation end products and dysregulated RAGE/AGER1 induce proinflammatory and fibrogenic signaling in NASH via NOX4
AASLD LiverLearning®, Ali Dehnad, 144571
Anti-fibrotic and anti-inflammatory effect of a novel LPA1 receptor antagonist, UD-009, in a mouse model of NASH.
AASLD LiverLearning®, Kenji Nishikawa, 144572
Mice with genetic deletion of ecto-nucleoside triphosphate diphosphohydrolase 3 (NTPDase3) are protected from development of both biliary and parenchymal-type liver fibrosis
AASLD LiverLearning®, Linda Feldbrugge, 144573
Effect of daclatasvir and asunaprevir combination therapy for chronic hepatitis or compensated cirrhosis by HCV genotype 1b infection with RAV negative population; from real world data.
AASLD LiverLearning®, Masatoshi Ishigami, 144829
Low hepatocelluar carcinoma (HCC) risk in HCV infected patients with liver cirrhosis or bridging fibrosis treated with different SOF-based DAA regimens: a single centre experience with a mean follow up of 12 months
AASLD LiverLearning®, Alessandra Mangia, 144830
Interferon, Ribavirin or Direct Antiviral Agent-Based Regimens for Treatment of Hepatitis C Among Patient with Porphyria Cutanea Tarda
AASLD LiverLearning®, Krishna Venkata, 144831
Disruption of Heat Shock Transcription Factor 1 (HSF1) reveals its essential role in protection from liver inflammation and fibrosis
AASLD LiverLearning®, Asmita Choudhury, 144587
Caveolin-1 targets lipid droplets formation in human hepatic stellate cells
AASLD LiverLearning®, Hiroaki Yokomori, 144588
Th2-polarization of CD4+ T-cells is locally induced and drives liver fibrogenesis
AASLD LiverLearning®, Johanna Reissing, 144589
The impact of IL28B polymorphism and HCV NS5A resistance associated variants on treatment response with ledipasvir and sofosbuvir regimen in Japanese real-life settings
AASLD LiverLearning®, Hitomi Sezaki, 144845
Uptake of HCV Therapy in HIV/HCV Coinfected Patients across Europe in the Era of Direct-Acting Antivirals
AASLD LiverLearning®, Lars Peters, 144846
Protease inhibitor and non-structural protein 5A inhibitor regimen can improve the health-related quality of life (HRQOL) in Japanese patients with genotype 1b hepatitis C virus
AASLD LiverLearning®, ikeda hiroki, 144847
Endoscopic Screening for large varices: increase in MELD score more predictive of variceal growth than calendar year
AASLD LiverLearning®, Sakkarin Chirapongsathorn, 144603
The comparison of long-term survival in cirrhotic patients with significant ascites and esophageal varices according to the treatment modality between endoscopic variceal ligation and non-selective beta-blockers
AASLD LiverLearning®, Jeong-Ju Yoo, 144604
Spleen stiffness is superior to liver stiffness for predicting esophageal varices in chronic liver disease: a meta-analysis
AASLD LiverLearning®, Xiaowen Ma, 144605
Sofosbuvir plus Ribavirin for difficult to treat HCV-2 : improved efficacy with extended treatment duration
AASLD LiverLearning®, Sara Piovesan, 144861
Efficacy and safety of the currently recommended regimens with direct acting antiviral(s) (DAA) in the treatment of chronic hepatitis C (CHC) patients in clinical practice. A Greek multicenter real-life cohort study.
AASLD LiverLearning®, George Papatheodoridis, 144862
Comorbidities, Co-medication and Potential Drug to Drug Interactions in Chronic Hepatitis C Patients (CHC): Implications for Adequate HCV Treatment Selection - Data from a large transversal study in Germany and France
AASLD LiverLearning®, Stefan Christensen, 144863
Extensive Economic and Quality of Life Burden of Viral Hepatitis (VH): The Data from the U.S. Medical Expenditure Panel Survey (MEPS)
AASLD LiverLearning®, Zobair Younossi, 144619
Factors associated with survival in a population-based cohort of patients with end-stage liver disease
AASLD LiverLearning®, David Goldberg, 144620
Impact of hepatitis C virus reflex testing on the hepatitis C care continuum among baby boomers in a urban health system
AASLD LiverLearning®, Aparna Goel, 144621
Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: the Canadian National Experience.
AASLD LiverLearning®, Bandar Aljudaibi, 144877
Safety and efficacy of Interferon-free antiviral treatment in Hepatitis C patients with MELD score 20 and over
AASLD LiverLearning®, Carmen Vinaixa, 144878
Patient reported assessment of different diagnostic imaging tests for liver disease - visual representation and ownership of results improves understanding.
AASLD LiverLearning®, Andy McKay, 144635
Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection
AASLD LiverLearning®, Brian McMahon, 144636
Improving Age-Based Hepatitis C Screening at a Veterans Affairs Primary Care Clinic
AASLD LiverLearning®, Jessica Rubin, 144637
Efficacy of direct-acting antiviral agents for treatment of HCV genotype 1 infection in Hispanics: data from a real-world cohort.
AASLD LiverLearning®, Andres Carrion, 144893
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in real life than expected from clinical trials
AASLD LiverLearning®, Stefan Mauss, 144894